Shots:

• The P-III REMDACTA study involves assessing of Actemra + remdesivir vs PBO + remdesivir in hospitalized patients with severe COVID-19 pneumonia receiving SOC with 1EPs & 2EPs as clinical status- mortality- mechanical ventilation & ICU variables. The study is expected to initiate the enrollment with a target of ~450 globally- including the US- Canada and EU in Jun’2020
• In addition to REMDACTA- the company has completed the enrollment in P-III COVACTA study assessing Actemra + SOC vs PBO + SOC in ~450 hospitalized patients with severe COVID-19 pneumonia across the globe
• Genentech has also initiated P-III EMPACTA study that will focus on enrolling ~375 patients at trial sites known to provide critical care to underserved and minority populations that often do not have access to clinical trials

Click here ­to­ read full press release/ article

Ref: Business wire | Image: Roche